### Legal Aspect of C. sativa  
_C. sativa_ and/or cannabis-based products have been legalized for medical use in 41 countries (23 in Europe) between 2012-2021. As _C. sativa_ and cannabis-based products are classified based on the \(\Delta^{9}\)-THC content with psychotropic properties, and most of them contain drug-type _C. sativa_ extracts, various legal limitations in many countries still exist. In total, 50 countries in Europe, Asia, North and South America use the plant for industrial purposes [29]. Cultivation and supply of 69 _C. sativa_ varieties [30] with \(\Delta^{9}\)-THC content not exceeding 0.2% is legal in EU [31], with some exclusions (Czech Republic and Austria, <0.3%, Switzerland 1.0%).The industrial use of _C. sativa_ is focused on production of >2500 products used in agriculture, textile production, recycling, automotive industry, furniture production, paper industry, production of construction materials, energy production, personal care products and medical supplements [29].  
Cultivation and use of marijuana, the crude drug derived from _C. sativa_ for recreational purposes, is not legalized in Europe, but it is decriminalized in 32 countries worldwide (16 in Europe), with various limitations regarding the amount of dry marijuana, number of cultivated plants and punishing public consumption [32].  
Several Pharmacopoeias, including the German pharmacopoeia (DAB), Swiss pharmacopoeia (Ph.Helv.), European Pharmacopoeia (Ph.Eur.), and the American Herbal Pharmacopoeia (AHP) comprise monographs defining _Cannabis_ flowers (\"Cannabis inflorescence\") as herbal substance that consists of whole or crushed, flowering, dried shoot tips of the female plants of _C. sativa_ L. (Cannabaceae) that contain 90.0-110.0% of the amounts of phytocannabinoids specified in the label, such as \(\Delta^{9}\)-THC and CBD, as well as cannabinoid carboxylic acids such as \(\Delta^{9}\)-THC and CBD, calculated as \(\Delta^{9}\)-THC or CBD, based on the dried drug [33; 34; 35; 36].  
Due to legal issues, chemotype classification of _C. sativa_ is nowadays much more significant. Depending on the content of \(\Delta^{9}\)-THC and CBD, authorities have classified generally three chemotypes of _C. sativa_ L.: \(\Delta^{9}\)-THC-predominant type, i.e., drug-type (CBD/\(\Delta^{9}\)-THC = 0.00-0.005), CBD-predominant type, i.e., fiber type (\"hemp\" type) (CBD/\(\Delta^{9}\)-THC = 15.0-25.0) and intermediate chemotype (CBD/\(\Delta^{9}\)-THC = 0.5-3.0) [37]. AHP proposes more comprehensive chemotype classification. Six chemotypes are defined: (1) type I-Drug (0.5-15% \(\Delta^{9}\)-THC; 0.01-0.16%CBD and 50:1 \(\Delta^{9}\)-THC/CBD ratio); type II-Intermediate (0.5-5% \(\Delta^{9}\)-THC; 0.9-7.3% CBD and 0.25/\(\sim\)2 \(\Delta^{9}\)-THC/CBD ratio); type III-Fiber (0.05-0.70% \(\Delta^{9}\)-THC; 1.0-13.6% CBD and <1:5 \(\Delta^{9}\)-THC/CBD ratio); type IV-CBG (<0.05% \(\Delta^{9}\)-THC; <0.5% CBD); type V-non-cannabinoid (\(\Delta^{9}\)-THC = 0; CBD = 0) [33]. In addition, DAB defines a discontinued cannabis extract-_Cannabis extractum norm_ as an extract from whole or shredded, flowering, dried shoot tips of the female plants of _C. sativa_ L. that contains \(\Delta^{9}\)-THC at least 1% and at most 25% (_m/m_) for the extract and 90.0 to 110.0% of the nominal salary specified in the label, and CBD maximum 10.0% (_m/m_) for the extract and 90.0 to 110.0% of the nominal content stated in the label [38]. High within-chemotype variability is recorded, due to changes in growing and storage conditions, such as environmental factors of cultivation (climates and elevation of cultivated area), the development stage of the plant at harvest time and genetic characteristics of seed-stocks [2; 17].